Eupraxia Pharmaceuticals closed at $7.81 on Nov 12, down 3.10%, 14.2% below its 52-week closing high. Volume of 398.5K shares was 0.68× its 20-day average (below normal).
Split-adjusted performance: +18.5% over one month, +9.1% over six months, +19.6% over one year.
Short interest was 6.2M shares at the Oct 30 settlement, down 4.5% from the prior report (75.0% of float, 10.4 days to cover).
No reported quarters with price history yet.
Not enough peers to rank
Eupraxia Pharmaceuticals Inc is a clinical-stage biotechnology company focused on the development of locally delivered, extended-release alternatives to existing pharmaceuticals. Its product EP-104 is used for the treatment of osteoarthritis and eosinophilic esophagitis symptoms. The company leverages its proprietary Diffusphere technology to optimize drug delivery for applications with unmet medical needs. Currently, the company has two distinct clinical development programs, one targeting EoE and the second targeting chronic Osteoarthritis pain in the knee and has completed a Phase 2b clinical trial with EP-104IAR in knee OA.
Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology
